Erdal Toprak: More Effective, Lower-Toxicity Combination Therapies for Acute Myeloid Leukemia
Erdal Toprak, Co-Founder of BAIT-Bio LLC, shared a post on LinkedIn:
“Our lab’s first cancer paper is now out! We systematically screened 105 clinically relevant drug pairs and quantified their interactions across six genetically diverse acute myeloid leukemia (AML) cell lines. We found that synergy and antagonism are prevalent but rarely conserved across different genetic backgrounds—an IDH2 mutation, for example, can flip a synergistic combination into an antagonistic one.
These genotype-specific insights can point the way toward more effective, lower-toxicity combination therapies. Read more.”
Title: Synergistic and antagonistic drug interactions are prevalent but not conserved across acute myeloid leukemia cell lines
Authors: Fatma Neslihan Kalkan, Muhammed Sadik Yildiz, N. Ezgi Wood, Michael Farid, Melissa McCoy, Milo M. Lin, Chengcheng Zhang, Bruce A. Posner, Stephen S. Chung, Erdal Toprak
Read the Full Article.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023